2021 BRN Discussion, page-17951

An interesting article which succinctly explains what Brainchip, Biotome and Cardea Bio are setting out to achieve:


Background to Biotome

Biotome, founded in 2017 by ProfessorSamuel Lundin, Dr Alma Fulurija and Nobel Laureate Professor Barry Marshall,is developing next-generation antibody tests (serology tests)based on precision immunology.

Their diagnostics involve smallpieces of proteins (i.e. peptides) instead of whole proteins as analysismarkers. This is a fundamental advantage compared to conventional serology, asit allows the full use of the high resolution of the immune system, resultingin higher precision and lower cost compared to conventional techniques.An added advantage is that the markers of Biotome’s tests are patentable,unlike conventional protein markers.

Biotome has three diagnostic projectsin the pipeline, each addressing large markets. The most progressedproject, Helitope^TM, is a simple bloodtest for stomach cancer risk. The two other projects are focused ondeveloping an antibody-test for COVID-19 (Covitope^TM) as well as a testfor the risk of pre-eclampsia development.

Biotome has astrong global network of partners and collaborators in industry, academia andthe health care sector.

Partnership with BrainChip Ltd in aProject Funded by the Government of Western Australia

BrainChip is a global technologycompany that is producing a groundbreaking Akida^TM neuromorphicprocessor chip that brings artificial intelligence to the edge in a way that isbeyond the capabilities of other products. In a joint government fundedCOVID-19 project Biotome will use Akida^TM to identifythe antibodies that can protect against SARS- CoV-2 infection – the so-called neutralisingantibodies. This could pave the way for a test that determines which level ofprotection against COVID-19 a person has after having received COVID-19vaccination or after having been infected with SARS-CoV-2.

Dr. Samuel Lundin, CEO of Biotome onthe BrainChip partnership:

“We believe the precision of antibodytests for infections can be improved dramatically. Our partnership withBrainchip is an important step for our development of point-of-care tests thatare based on patented high-precision immunological markers. We are very excitedto explore how the cutting-edge Akida neural processor can improve the accuracyand information quality of the antibody-tests we are developing, by providingadvanced AI capacity at the point of care. If the project is successful we willapply the same principles to other antibody tests in our pipeline.”

Linking Biology up to Computers withCardea Bio Inc

Biotome engages with partnercompanies across the globe that can provide point-of-care diagnostic platformsthat can be adapted to work with our patented peptide markers. Recently, atechnology partnership has been entered with Cardea Bio Inc., a US-based globalleader in nanoelectronics manufacturing and the only mass-producer ofgraphene-based biological transistors. Through joining Cardea’s InnovationPartnership Program, Biotome will leverage Cardea’s graphene field effecttransistors to connect biology with modern electronics for high-precisionimmunology diagnostics, to address the unparalleled global demand for rapid,accurate diagnostic tests.

Graphene-based Cardean Transistors^TM for precisionimmunology diagnostics

Current Capital Raising Round

Biotome is currently raising capitalto cover costs for progressing the three ongoing projects. This round has sofar raised $380k from existing and new investors, and the round will close inQ3 2021. For more information, contact CEO Dr Samuel Lundin – [email protected].

About Biotome Pty Ltd

Biotome is at the forefront ofnext-generation serology research, which has the potential to drasticallyimprove the performance of diagnostics, ushering in the new era of precisionimmunology. Using our technology, we discover patentable immunological markersof superior accuracy across a range of diseases. Through strategicpartnerships, Biotome integrates linear epitopes with cutting-edge diagnosticassay platforms to access the intrinsic high resolution of the immune system,addressing unmet needs through the development of precision immunologydiagnostics.

https://wholesaleinvestor.com.au/biotome-pty-ltd-advances-precision-immunology-with-cutting-edge-ai-and-nanoelectronics/

My opinion only DYOR
FF

AKIDA BALLISTA